Literature DB >> 8612046

Antiviral effect of phosphorothioate oligodeoxyribonucleotides complementary to human immunodeficiency virus.

S G Kim1, T Hatta, S Tsukahara, H Nakashima, N Yamamoto, Y Shoji, K Takai, H Takaku.   

Abstract

Modifications of oligodeoxyribonucleotides include the replacement of the backbone phosphodiester groups with phosphorothioate (S-ODNs) groups and the substitution of phosphorothioate (SO-ODNs) groups at both the 3'- and 5'-ends. In assays for HIV, oligomers (S-ODNs) were more active at the micromolar range than were SO-ODNs of the same sequence. Furthermore, the abilities of antisense-, sense-, random-, and mismatched-oligomers, or homo-oligomers containing internucleotidic phosphorothioate linkages to inhibit HIV-1 replication were examined. Antisense oligonucleotides inhibit the replication and the expression of HIV-1 more efficiently than random-, sense-, mismatched-, and homo-oligomers of the same length or with the same internucleotide modification. Five different target sites (gag, pol, rev, tat, and tar) within the HIV genes were also studied with regard to the inhibition of HIV replication by antisense oligonucleotides. Antisense oligomers complementary to the sites of initiation sequences and to certain splice sites were most effective. The effect of antisense oligomer length on inhibiting viral replication was also investigated. Of particular interest was the S-ODNs-rev 15 mer, which possessed higher anti-HIV activity than the sense-, random-, mismatched-, and homo-20 mers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8612046      PMCID: PMC9212667          DOI: 10.1016/0968-0896(94)00142-p

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.461


  33 in total

1.  Nucleotide sequence of the AIDS virus, LAV.

Authors:  S Wain-Hobson; P Sonigo; O Danos; S Cole; M Alizon
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

2.  Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.

Authors:  R Pauwels; J Balzarini; M Baba; R Snoeck; D Schols; P Herdewijn; J Desmyter; E De Clercq
Journal:  J Virol Methods       Date:  1988-08       Impact factor: 2.014

3.  Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site.

Authors:  M Lemaitre; B Bayard; B Lebleu
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

4.  Three novel genes of human T-lymphotropic virus type III: immune reactivity of their products with sera from acquired immune deficiency syndrome patients.

Authors:  S K Arya; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

5.  Control of ribonucleic acid function by oligonucleoside methylphosphonates.

Authors:  P S Miller; C H Agris; L Aurelian; K R Blake; A Murakami; M P Reddy; S A Spitz; P O Ts'o
Journal:  Biochimie       Date:  1985 Jul-Aug       Impact factor: 4.079

6.  Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates.

Authors:  J Lisziewicz; D Sun; V Metelev; P Zamecnik; R C Gallo; S Agrawal
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

7.  Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages.

Authors:  Y Shoji; S Akhtar; A Periasamy; B Herman; R L Juliano
Journal:  Nucleic Acids Res       Date:  1991-10-25       Impact factor: 16.971

8.  Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA.

Authors:  E L Wickstrom; T A Bacon; A Gonzalez; D L Freeman; G H Lyman; E Wickstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

9.  Phosphorothioate and normal oligodeoxyribonucleotides with 5'-linked acridine: characterization and preliminary kinetics of cellular uptake.

Authors:  C A Stein; K Mori; S L Loke; C Subasinghe; K Shinozuka; J S Cohen; L M Neckers
Journal:  Gene       Date:  1988-12-10       Impact factor: 3.688

10.  Tetrazolium-based plaque assay for HIV-1 and HIV-2, and its use in the evaluation of antiviral compounds.

Authors:  H Nakashima; R Pauwels; M Baba; D Schols; J Desmyter; E De Clercq
Journal:  J Virol Methods       Date:  1989-12       Impact factor: 2.014

View more
  4 in total

1.  Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production.

Authors:  Neerja Kaushik; Amartya Basu; Paul Palumbo; Rene L Myers; Virendra N Pandey
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.

Authors:  S Sei; Q E Yang; D O'Neill; K Yoshimura; K Nagashima; H Mitsuya
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Lipid-based delivery of combinations of antisense oligodeoxynucleotides for the in vitro inhibition of HIV-1 replication.

Authors:  C Lavigne; J Yelle; G Sauvé; A G Thierry
Journal:  AAPS PharmSci       Date:  2001

4.  Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.

Authors:  Moizza Mansoor; Alirio J Melendez
Journal:  Gene Regul Syst Bio       Date:  2008-09-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.